Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial

Affiliations

• ¹ Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, UnIC@RISE, University of Porto, Porto, Portugal. [email protected].
• ² INSERM, Centre d'Investigations Cliniques - Plurithématique 14-33, Université de Lorraine, and INSERM U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. [email protected].
• ³ CIM - Centro de Investigação Médica, Faculdade de Medicina UP - Piso 6 - DCF, Rua Plácido da Costa, S/N, 4200-450, Porto, Portugal. [email protected].
• ⁴ Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, Glasgow, UK.
• ⁵ INSERM, Centre d'Investigations Cliniques - Plurithématique 14-33, Université de Lorraine, and INSERM U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
• ⁶ Department of Cardiology, CARIM, Maastricht University Medical Centre, Maastricht, The Netherlands.
• ⁷ Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands.
• ⁸ London School of Hygiene and Tropical Medicine, London, UK.
• ⁹ Department of Internal Medicine and Cardiology, German Centre for Cardiovascular Research (DZHK), Charité University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany.
• ¹⁰ Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, UK.
• ¹¹ Research Institute Alliance for the Promotion of Preventive Medicine, Mechelen, Belgium.